Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02663323
Other study ID # MER/EX
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 2, 2016
Est. completion date July 5, 2020

Study information

Verified date August 2018
Source Meril Life Sciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe, Brazil and South Africa. Primary outcome of study will be Proportion of population reporting Major Adverse Cardiac Events at 6 months from the day of index Procedure.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 64
Est. completion date July 5, 2020
Est. primary completion date October 5, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

General Inclusion Criteria:

1. Male or female subjects = 18 years of age

2. Subject is able to sign written Informed Consent Form (ICF)

3. Subjects with symptomatic myocardial ischemia, chronic stable angina

4. The patient has planned intervention of a single de novo lesion in native epicardial vessel

5. Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)

6. Subject is not participating in any other clinical investigation/study and agrees not to participate in any other clinical investigation/study for a period of 3 years following the index procedure.

7. Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms and OCT as per protocol.

Angiographic Inclusion Criteria:

1. Subject with maximum two treatable de novo lesions located maximum one per native epicardial vessel located in major artery or branch, with reference vessel diameter between 2.75, 3.00 and 3.5 mm by on line QCA.

2. Target lesion length = 20 mm.

3. Subjects with Lesion(s), with a visually estimated stenosis of = 50% and < 100% with a TIMI flow of = 1.

Exclusion Criteria:

General Exclusion Criteria:

1. Subjects unable to provide written informed consent.

2. Pregnant or nursing mother and those who plan pregnancy during the clinical investigation (female patients must have a negative pregnancy test done within 7 days prior to the index procedure and effective contraceptive must be used during participation in this clinical investigation).

3. Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA), Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine, prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet therapy including aspirin, both heparin and bivalirudin.

4. Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment changes in Electro Cardio Gram (ECG).

5. Subject with history of previous revascularization procedures including CABG and Percutaneous Coronary Intervention (PCI).

6. Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure having LVEF < 30%, cardiac tamponade.

7. Recipient of an organ in an organ transplant procedure or is on a waiting list for any organ transplant.

8. Subjects receiving immunosuppression therapy or having known immunosuppressive or autoimmune disease.

9. Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic neurological Attack (TIA). Patients with renal insufficiency where creatinine levels are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count <100,000 cells/mm3, a WBC of < 3,000 cells/mm3.

10. Subjects planned for elective surgery within the first 12 months after the procedure that will require discontinuing dual antiplatelet therapy

11. Subject has a history of bleeding diathesis or coagulatory disease, refuses blood transfusion, significant gastrointestinal or urinary bleed within the past 12 months.

12. Subject having extensive peripheral vascular disease that precludes safe 6F sheath insertion.

13. Subject having a history of paradoxical exercise induced vasoconstriction that is consistent with myocardial bridging in the coronary anatomy.

14. Subjects participating in another clinical investigation.

15. Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that would limit compliance with the follow-up schedule of the study.

Angiographic Exclusion Criteria:

1. Subjects who are non-candidates for PCI.

2. Any of the target lesions meets any of the following criteria:

1. Aorto-ostial location (within 3 mm)

2. Lesion located in left main coronary artery

3. Lesion located within 2 mm of origin of the LAD or LCx

4. Lesion that involves a bifurcation with a side branch = 2mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring intervention

5. Total occlusion (TIMI Flow 0), prior to wire crossing

6. Extreme tortuosity proximal to or within the lesion

7. Lesions having heavy calcification

8. Extreme angulation (= 90 %) proximal to or within the lesion

3. Evidence of previous revascularization:

1. Previous PCI with or without restenosis from previous intervention

2. Arterial or venous graft with or without lesion located within the graft or distal to a diseased arterial or saphenous vein graft

4. The target vessel contains visible thrombus.

5. Another (clinically significant or potentially significant) lesion left untreated within target vessels (including side branch) or another significant vessel.

6. Subject requiring or potentially requiring interventional procedures other than pre-dilatation and study device implantation and post dilatation.

Study Design


Intervention

Device:
MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.

Locations

Country Name City State
Brazil Instituto Dante Pazzanese de Cardiologia Sao Paulo SP
Indonesia Medistra Hospital Jakarta
Macedonia, The Former Yugoslav Republic of University Clinic of Cardiology Skopje
Malaysia Institut Jantung Negara Kuala Lumpur

Sponsors (1)

Lead Sponsor Collaborator
Meril Life Sciences Pvt. Ltd.

Countries where clinical trial is conducted

Brazil,  Indonesia,  Macedonia, The Former Yugoslav Republic of,  Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure. 6 Month
Primary Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure 6 Month
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A